Glucosamine, chondroitin, collagen make up the standard joint-supplement stack, and all three aim at the same target i.e. cartilage. That’s a reasonable place to look, but it may not be where the actual structural fight is happening. Sitting just beneath the cartilage is subchondral bone, and a specific protein there needs vitamin K to do its most basic job which is of keeping calcium out of tissue that shouldn’t be calcifying in the first place. Most joint formulas don’t touch that pathway at all.
The Protein Most Joint Supplements Never Mention
Matrix Gla protein (MGP) is a vitamin K-dependent protein whose job is to inhibit calcification in cartilage and bone, the same protective role it plays in blood vessels. A 2020 review in Nutrients collated the evidence connecting vitamin K status to osteoarthritis and concluded that sufficient vitamin K is consistently associated with a lower risk of OA and fewer pathological joint features, largely through this calcification-inhibiting mechanism (Chin, 2020). The review was clear that clinical trial evidence is still limited, this is an association-and-mechanism story more than a proven-treatment one but the biological logic holds up: no active MGP, no brake on calcium building up where it doesn’t belong.
What Turned Up in Actual Knee-Replacement Tissue
The most direct evidence comes from bone itself. Japanese researchers measured vitamin K2 levels in bone harvested during 58 total knee replacement surgeries, comparing the more weight-bearing, more degenerated side of each joint to the less-degenerated side (Ishii et al., 2013). The less-degenerated compartments contained significantly more vitamin K2 than the more-degenerated ones (p < .0001). The vitamin wasn’t just theoretically relevant to the joint, it was measurably depleted in the exact bone showing the most damage.
What Happens When Vitamin K Gets Blocked
The clearest population-level signal comes from watching what happens when vitamin K’s activity is deliberately shut off. Researchers tracked acenocoumarol use — a vitamin K-blocking anticoagulant against osteoarthritis incidence and progression in 3,494 participants of the long-running Rotterdam Study (Boer et al., 2021):
| Outcome (vitamin K blocked by anticoagulant use) | Increased risk vs. non-users | Odds ratio |
| Osteoarthritis, overall incidence + progression | More than doubled | OR = 2.50 |
| Knee osteoarthritis specifically | More than doubled | OR = 2.34 |
| Hip osteoarthritis specifically | Nearly tripled | OR = 2.74 |
Source: Boer, Szilagyi, Nguyen, Neogi, Meulenbelt, Ikram, Uitterlinden, Bierma-Zeinstra, Stricker, & van Meurs (2021).
The researchers noted this doesn’t prove the anticoagulant itself is the cause, shared underlying health factors could play a role but it lines up with the mechanism: block vitamin K, and joint calcification-related damage accelerates.
Why Form Matters for a Slow-Building Problem
Cartilage and subchondral bone break down over years, not weeks, which makes steady vitamin K status more relevant than an occasional dose. A bioavailability study found that after a single dose, MK-7 stayed detectable in serum for up to 48 hours, while MK-4 at the same dose wasn’t detectable at any point measured (Sato et al., 2012). A form that clears the bloodstream within hours is a weaker fit for a joint-support formula meant to be taken daily over years.
Where TerraQuino Fits In
TerraQuino produces MK-7 through a controlled fermentation process, delivering the long-chain, allergen-free vitamin K2-7 associated with the sustained blood levels documented above.
It’s formulated for tablets, capsules, softgels, sachets, and liquids, and pairs cleanly with glucosamine, chondroitin, collagen, and vitamin D3 in combination joint formulas.
TerraQuino doesn’t make treatment claims for osteoarthritis, the clinical trial evidence isn’t there yet but it gives formulators a bioavailability-tested K2 source to add to a category that has largely ignored this mechanism.
FAQs
Can vitamin K2 replace glucosamine or chondroitin in a joint supplement?
No, it addresses a different mechanism (calcium regulation in subchondral bone) rather than cartilage matrix building, which is what glucosamine and chondroitin target. The research suggests it’s a complementary addition, not a substitute (Chin, 2020).
Does this mean blood thinners cause osteoarthritis?
The Rotterdam Study found a strong association between vitamin K-blocking anticoagulants and OA risk, not proof of direct causation (Boer et al., 2021). Anyone on these medications should never stop or adjust them without talking to their prescribing doctor, the cardiovascular risk they manage is not optional.
Is this specific to knees, or does it apply to other joints too?
The strongest direct tissue evidence is from knee-replacement bone (Ishii et al., 2013), and the Rotterdam Study found the association held for both knee and hip OA (Boer et al., 2021). The mechanism of MGP inhibiting calcification isn’t knee-specific, though most of the joint-specific research so far has focused there.
Should I look for vitamin K1 or K2 on a joint supplement label?
Most of the mechanistic and tissue-level joint research centers on K2 specifically, and MK-7 is generally preferred in supplements for its longer half-life compared to K1 or MK-4 (Sato et al., 2012).
References
Boer, C. G., Szilagyi, I., Nguyen, N. L., Neogi, T., Meulenbelt, I., Ikram, M. A., Uitterlinden, A. G., Bierma-Zeinstra, S., Stricker, B. H., & van Meurs, J. B. (2021). Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis. Annals of the Rheumatic Diseases, 80(7), 943–947. https://doi.org/10.1136/annrheumdis-2020-219483
Chin, K.-Y. (2020). The relationship between vitamin K and osteoarthritis: A review of current evidence. Nutrients, 12(5), Article 1208. https://doi.org/10.3390/nu12051208
Ishii, Y., Noguchi, H., Takeda, M., Sato, J., Yamamoto, N., Wakabayashi, H., Kanda, J., & Toyabe, S. (2013). Distribution of vitamin K2 in subchondral bone in osteoarthritic knee joints. Knee Surgery, Sports Traumatology, Arthroscopy, 21(8), 1813–1818. https://doi.org/10.1007/s00167-012-2239-4
Sato, T., Schurgers, L. J., & Uenishi, K. (2012). Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutrition Journal, 11, Article 93. https://doi.org/10.1186/1475-2891-11-93
